Preferred Label : Cerdulatinib;
NCIt synonyms : Syk/JAK Inhibitor PRT062070;
NCIt related terms : Syk-JAK Inhibitor PRT062070;
NCIt definition : An orally bioavailable dual inhibitor of spleen tyrosine kinase (Syk) and Janus-associated
kinases (JAK), with potential anti-inflammatory and antineoplastic activity. Upon
oral administration, cerdulatinib specifically binds to and inhibits the activity
of Syk, JAK1, and JAK3 with preferential inhibition of JAK1 and JAK3-dependent cytokine-mediated
signaling and functional responses. This negatively affects the downstream JAK-STAT
(signal transducer and activator of transcription) pathway, and leads to both reduced
inflammation in various animal models and enhanced antiproliferative activity towards
non-Hodgkin's lymphoma (NHL) cell lines. Syk is a non-receptor cytoplasmic tyrosine
kinase involved in signal transduction in cells of hematopoietic origin including
B cells, macrophages, basophils and neutrophils. Abnormal function of Syk has been
implicated in several hematopoietic malignancies including NHL and chronic lymphocytic
leukemia (CLL). The JAK-STAT pathway plays a key role in the signaling of many cytokines
and growth factors and is involved in cellular proliferation, growth, hematopoiesis,
and the immune response; JAK kinases may be upregulated in inflammatory diseases,
myeloproliferative disorders, and various malignancies.;
UNII : D1LXQ45S1O;
InChIKey : BGLPECHZZQDNCD-UHFFFAOYSA-N;
CAS number : 1198300-79-6;
Molecule name : PRT-062070;
Origin ID : C113173;
UMLS CUI : C4045924;
Currated CISMeF NLP mapping
- Semantic type(s)
- concept_is_in_subset
- has_target
